robotic microarrayer

Uncovering molecular targets for personalized treatment at CCR

Posted: Aug 4, 2016

Highthroughput screening uncovers molecular targets for treatment.

Uncovering molecular targets for personalized treatment at CCR

Incredibly exciting time in cancer treatment

Posted: Aug 1, 2016

CCR’s Bill Dahut, Acting Scientific Director for Clinical Research, discusses the incredible advances in oncology–and the complexities they pose–in an article by Popular Science.

Incredibly exciting time in cancer treatment

CCR study: evidence for benefit of TARP vaccine for men with early stage prostate cancer

Posted: Jul 27, 2016

Results from a pilot clinical trial found that TARP, or T-cell receptor gamma chain alternate reading frame protein, vaccination slowed prostate-specific antigen (PSA) rise in the majority of patients with early stage prostate cancer.

CCR study: evidence for benefit of TARP vaccine for men with early stage prostate cancer

Ira Pastan discusses his latest research on immunotoxins targeting mesothelin

Posted: Jul 27, 2016

Watch Dr. Ira Pastan explain his recently published research on the next generation of immunotoxins targeting mesothelin

Ira Pastan discusses his latest research on immunotoxins targeting mesothelin

CCR team uncovers a new principle in chemotherapy resistance in breast cancer

Posted: Jul 20, 2016

A study by a team of CCR investigators has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.

CCR team uncovers a new principle in chemotherapy resistance in breast cancer

CCR researchers find DNA-binding triggers tetramerization of glucocorticoid receptor in live cells

Posted: Jul 7, 2016

The glucocorticoid receptor (GR) is a ligand-regulated transcription factor and one of the most targeted proteins in the pharmaceutical industry due to its powerful antiinflammatory actions. The search for side effects-free glucocorticoids relies exclusively on a model wherein the GR oligomerization state, whether a monomer or a dimer, dictates its transcriptional output. Here, Dr. Gordon Hager, Dr. Diego Presman, and colleagues use an experimental approach where the GR–DNA interaction is observed in real time with a technique that allows the quantification of the oligomeric state of proteins in living cells. Unexpectedly, they find that DNA binding triggers tetramerization of the GR, which would be the truly activated form of the receptor. Their findings reveal a previously unidentified step in the glucocorticoid activation pathway.

CCR researchers find DNA-binding triggers tetramerization of glucocorticoid receptor in live cells

CCR investigators use liquid biopsies to uncover cancer in the blood of lymphoma patients

Posted: Jun 28, 2016

CCR investigators are using circulating tumor DNA (ctDNA) as a type of noninvasive liquid biopsy for patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma. are using circulating tumor DNA (ctDNA) as a type of noninvasive liquid biopsy for patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma.

CCR investigators use liquid biopsies to uncover cancer in the blood of lymphoma patients
human papillomavirus

CCR Connections | Volume 10 - No 1

Posted: Jun 27, 2016

The latest issue of CCR connections is out now, check it out!

CCR Connections | Volume 10 - No 1

New developments in active surveillance for prostate cancer

Posted: Jun 27, 2016

Drs. Peter Choyke (Molecular Imaging Program, CCR) and Stacy Loeb (New York University Langone Medical Center) talk to CancerNetwork about the progress that has been made in active surveillance for prostate cancer.

New developments in active surveillance for prostate cancer

Pages